Loading
A phase 3 trial in lung cancer, run by Fudan University, now recruiting.
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) is a phase 3, interventional study registered as NCT05717803 by Fudan University, with a registry enrolment figure of 307 participants, started 2023-02-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Segmentectomy. Conditions listed: Segmentectomy; Lung Adenocarcinoma. Primary outcome: 5-year disease-free survival. Lung eligibility wording from the registry: "* Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.